Join
Live feed
·
INSIDERFilingvia Quantisnow
Syndax Pharmaceuticals Inc. logo

Director Katkin Keith bought $91,120 worth of shares (10,000 units at $9.11), increasing direct ownership by 11% to 100,000 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
SNDX· Syndax Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNDX (Syndax Pharmaceuticals Inc.) and more on Quantisnow.